Table 1: Characteristics of Included Studies.

Study IDGender male/femaleBase-line informationAverage age (years)InterventionsControlDuration of treatment (days)Outcome measures

Ji and Yin 2006  [10]59/35Age, sex, condition45.2Astragalus injection (250 mL i.d, qd)5% glucose injection30 -MG, mAlb
Hua et al. 2009  [17]84/43Age, sex, blood pressure, duration44.3Astragalus injection (250 mL i.d, qd) calcium channel blockers (CCB), ACEI/ARB, thiazine diureticsCCB,ACEI/ARB, thiazine diuretics20Twenty-four hours urinary protein content, blood pressure, urinalysis, renal function
Xu et al. 2008  [11]28/20Age, sex, blood pressure Astragalus injection (250 mL i.d, qd) Telmisartan, PlendilTelmisartan, Plendil21Twenty-four hours urinary protein content, blood pressure, mAlb, serum potassium, pulse pressure, estimated glomerular filtration rate (eGFR)
He 2004  [12]78/18Age, sex74.2Astragalus injection (500 mL i.d, qd)Prostaglandin (PGE1)15BUN, Scr, Ccr
Yao et al. 2002  [13]38/26Age, sex, blood pressure Astragalus injection (250 mL i.d, qd) Lotensin, PlendilLotensin, Plendil21Twenty-four hours urinary protein content